Financing ·
Viking Therapeutics raises $547.8M via equity and debt offering to fund clinical programs
VKTXViking Therapeutics, Inc.
Viking Therapeutics, Inc. completed a combined equity and debt offering on September 25, 2026, raising approximately $547.8 million in net proceeds. The company issued 9,035,714 shares of common stock at $35.00 per share, generating roughly $297.0 million after underwriting discounts and the full exercise of the over-allotment option. Simultaneously, it sold $258,750,000 aggregate principal amount of 2.00% Convertible Senior Notes due 2032, yielding approximately $250.8 million in net proceeds. The convertible notes carry an initial conversion price of roughly $50.75 per share and mature on October 15, 2032. Proceeds will fund the clinical development of VK2735 and VK3019 programs, along with general corporate purposes. Viking Therapeutics operates in the biotechnology industry, focusing on drug discovery and development.